

## **APPENDIX A**

### **The Amended Claims With Editing Indicia and the Newly Added Claims**

28. (Amended) A method of making an antibody that specifically binds to phosphatidylserine, said method comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of [a phosphatidylcholine/polypeptide or] a phosphatidylserine/polypeptide conjugate composition.
37. (New) The method of claim 29, wherein said polypeptide is  $\beta_2$ -glycoprotein I.
38. (New) The method of claim 28, wherein the antibody is linked to a detectable label.
39. (New) The method of claim 38, wherein the antibody is linked to a radioactive label, a fluorogenic label, a nuclear magnetic spin resonance label, biotin or an enzyme that generates a detectable product upon contact with a chromogenic substrate.
40. (New) The method of claim 38, wherein the antibody is linked to an alkaline phosphatase, hydrogen peroxidase or glucose oxidase enzyme.
41. (New) The method of claim 28, wherein the antibody is a monoclonal antibody.
42. (New) A method of making an antibody that specifically binds to phosphatidylserine, said method comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylserine/polypeptide conjugate composition, wherein the phosphatidylserine/polypeptide conjugate composition is not a phosphatidylserine/KLH conjugate composition.
43. (New) The method of claim 42, wherein the pharmaceutical composition comprises a phosphatidylserine/BSA, phosphatidylserine/BGG, or phosphatidylserine/ $\beta_2$ -glycoprotein I conjugate.

44. (New) The method of claim 43, wherein said polypeptide is  $\beta_2$ -glycoprotein I.
45. (New) The method of claim 42, wherein the antibody is linked to a detectable label.
46. (New) The method of claim 45, wherein the antibody is linked to a radioactive label, a fluorogenic label, a nuclear magnetic spin resonance label, biotin or an enzyme that generates a detectable product upon contact with a chromogenic substrate.
47. (New) The method of claim 45, wherein the antibody is linked to an alkaline phosphatase, hydrogen peroxidase or glucose oxidase enzyme.
48. (New) The method of claim 42, wherein the antibody is a monoclonal antibody.
49. (New) A method of making a monoclonal antibody that specifically binds to phosphatidylserine, said method comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylserine/polypeptide conjugate composition.
50. (New) The method of claim 49, wherein the pharmaceutical composition comprises a phosphatidylserine/BSA, phosphatidylserine/BGG, or phosphatidylserine/ $\beta_2$ -glycoprotein I conjugate.
51. (New) The method of claim 50, wherein said polypeptide is  $\beta_2$ -glycoprotein I.
52. (New) The method of claim 49, wherein the antibody is linked to a detectable label.
53. (New) The method of claim 52, wherein the antibody is linked to a radioactive label, a fluorogenic label, a nuclear magnetic spin resonance label, biotin or an enzyme that generates a detectable product upon contact with a chromogenic substrate.

54. (New) The method of claim 52, wherein the antibody is linked to an alkaline phosphatase, hydrogen peroxidase or glucose oxidase enzyme.